Epigenetic modifications in human thyroid cancer (review)

Biomedical Reports

Volumn 3, Issue 1, 2015, Pages 3-8

  Faam, Bita ^a   Ali Ghaffari, Mohammad ^b   Ghadiri, Ata ^a   Azizi, Fereidoun ^c  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

DNA methylation; Epigenetic; Microrna; Thyroid cancer

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; MASPIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH4 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAP PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SERINE PROTEINASE INHIBITOR; SODIUM IODIDE SYMPORTER; THYROGLOBULIN; THYROID PEROXIDASE; THYROTROPIN RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ARTICLE; AUTOSOME; CANCER INCIDENCE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CHROMOSOME ABERRATION; DNA METHYLATION; EPIGENETIC MODIFICATION; EPIGENETIC REPRESSION; EPIGENETICS; GENE EXPRESSION; GENE LOCUS; GENE OVEREXPRESSION; GENETIC VARIABILITY; HORMONAL CARCINOGENESIS; HUMAN; MUTATION; ONCOGENE RAS; ONCOGENE RET; PROTO ONCOGENE; THYROID CANCER; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84922148274     PISSN: 20499434     EISSN: 20499442     Source Type: Journal    
DOI: 10.3892/br.2014.375     Document Type: Article

References (69)

1. Shirazi HA, Hedayati M, Daneshpour MS, Shafiee A and Azizi F: Analysis of loss of heterozygosity effect on thyroid tumor with oxyphilia cell locus in familial non medullary thyroid carcinoma in Iranian families. Indian J Hum Genet 18: 340-343, 2012.
2. Patel KN and Shaha AR: Poorly differentiated and anaplastic thyroid cancer. Cancer Control 13: 119-128, 2006.
3. Fassnacht M, Kreissl MC, Weismann D and Allolio B: New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 123: 117-141, 2009.
4. Ghossein R: Problems and controversies in the histopathology of thyroid carcinomas of follicular cell origin. Arch Pathol Lab Med 133: 683-691, 2009.
5. Hedayati M, Zarif Yeganeh M, Sheikhol Eslami S, Rezghi Barez S, Hoghooghi Rad L and Azizi F: Predominant RET germline mutations in exons 10, 11, and 16 in Iranian patients with hereditary medullary thyroid carcinoma. J Thyroid Res 2011: 264248, 2011.
6. Kondo T, Ezzat S and Asa SL: Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6: 292-306, 2006.
7. Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245-262, 2005.
8. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF and de Micco C: Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88: 2745-2752, 2003.
9. Hedayati M, Nabipour I, Rezaei-Ghaleh N and Azizi F: Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases. Med J Malaysia 61: 564-569, 2006.
10. Nikiforov YE: RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13: 3-16, 2002.
11. Bethanis S, Koutsodontis G, Palouka T, et al: A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A. Hormones (Athens) 6: 152-156, 2007.
12. Lips CJ, Hӧppener JW and Thijssen JH: Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. Ann Clin Biochem 38: 168-179, 2001.
13. Musholt TJ, Schӧnefeld S, Schwarz CH, et al: Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation. Langenbecks Arch Surg 395: 877-883, 2010.
14. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457, 2003.
15. Nikiforova MN, Kimura ET, Gandhi M, et al: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88: 5399-5404, 2003.
16. Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis 31: 27-36, 2010.
17. Egger G, Liang G, Aparicio A and Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463, 2004.
18. Katz TA, Huang Y, Davidson NE and Jankowitz RC: Epigenetic reprogramming in breast cancer: from new targets to new therapies. Ann Med 24: 1-12, 2014.
19. Kondo T, Nakazawa T, Ma D, et al: Epigenetic silencing of TTF-1/NKX2,1 through DNA hypermethylation and histon H3 modification in thyroid carcinoma. Lab invest 89: 791-799, 2009.
20. Moon JW, Lee SK, Lee JO, et al: Identification of novel hypermethylated genes and demethylationg effect of vincristine in colorectal cancer. J Exp Clin Cancer Res 33: 4, 2014.
21. Jones PA and Baylin SB: The epigenomics of cancer. Cell 128: 683-692, 2007.
22. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003.
23. Eden A, Gaudet F, Waghmare A and Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300: 455, 2003.
24. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
25. Cantley LC and Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96: 4240-4245, 1999.
26. Chu EC and Tarnawski AS: PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monit 10: RA235-RA241, 2004.
27. Alvarez-Nuñez F, Bussaglia E, Mauricio D, et al; Thyroid Neoplasia Study Group: PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 16: 17-23, 2006.
28. Pfeifer GP and Dammann R: Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc) 70: 576-583, 2005.
29. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP and Dammann R: Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 62: 3698-3701, 2002.
30. Xing M, Cohen Y, Mambo E, et al: Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 64: 1664-1668, 2004.
31. Qi JH, Ebrahem Q, Moore N, et al: A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 9: 407-415, 2003.
32. Hoque MO, Rosenbaum E, Westra WH, et al: Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab 90: 4011-4018, 2005.
33. Hu S, Liu D, Tufano RP, et al: Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer 119: 2322-2329, 2006.
34. De Falco V, Castellone MD, De Vita G, et al: RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. Cancer Res 67: 381-390, 2007.
35. Gao L, Feng Y, Bowers R, et al: Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. Cancer Res 66: 7880-7888, 2006.
36. Wang Z, Dillon TJ, Pokala V, et al: Rap1-mediated activation of extracellular signal-regulated kinases by cyclic AMP is dependent on the mode of Rap1 activation. Mol Cell Biol 26: 2130-2145, 2006.
37. Zhang L, Chenwei L, Mahmood R, et al: Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer. Cancer Res 66: 898-906, 2006.
38. Zhang Z, Mitra RS, Henson BS, et al: Rap1GAP inhibits tumor growth in oropharyngeal squamous cell carcinoma. Am J Pathol 168: 585-596, 2006.
39. Nellore A, Paziana K, Ma C, et al: Loss of Rap1GAP in papillary thyroid cancer. J Clin Endocrinol Metab 94: 1026-1032, 2009.
40. Tsygankova OM, Prendergast GV, Puttaswamy K, et al: Downregulation of Rap1GAP contributes to Ras transformation. Mol Cell Biol 27: 6647-6658, 2007.
41. Rodríguez-Rodero S, Fernández AF, Fernández-Morera JL, et al: DNA methylation signatures identify biologically distinct thyroid cancer subtypes. J Clin Endocrinol Metab 98: 2811-2821, 2013.
42. Ogasawara S, Maesawa C, Yamamoto M, et al: Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers. Oncogene 23: 1117-1124, 2004.
43. Xing M, Usadel H, Cohen Y, et al: Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res 63: 2316-2321, 2003.
44. Faam B, Daneshpour MS, Azizi F, Salehi M and Hedayati M: Association between TPO gene polymorphisms and anti-TPO level in Tehranian population: TLGS. Gene 498: 116-119, 2012.
45. Eze OP, Starker LF and Carling T: The role of epigenetic alterations in papillary thyroid carcinogenesis. J Thyroid Res 2011: 895470, 2011.
46. Xing M: Gene methylation in thyroid tumorigenesis. Endocrinology 148: 948-953, 2007.
47. He H, Jazdzewski K, Li W, et al: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102: 19075-19080, 2005.
48. Kitamura Y and Hirotab S: Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 61: 2924-2931, 2004.
49. Weber F, Teresi RE, Broelsch CE, Frilling A and Eng C: A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 91: 3584-3591, 2006.
50. Gallagher WM, Greene LM, Ryan MP, et al: Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues. FEBS Lett 489: 59-66, 2001.
51. Schulte KM, Jonas C, Krebs R and Rӧher HD: Activin A and activin receptors in thyroid cancer. Thyroid 11: 3-14, 2001.
52. Abraham D, Jackson N, Gundara JS, et al: MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin Cancer Res 17: 4772-4781, 2011.
53. Mian C, Pennelli G, Fassan M, et al: MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Thyroid 22: 890-896, 2012.
54. Lagos-Quintana M, Rauhut R, Lendeckel W and Tuschl T: Identification of novel genes coding for small expressed RNAs. Science 294: 853-858, 2001.
55. Frezzetti D, De Menna M, Zoppoli P, et al: Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene 30: 275-286, 2011.
56. Zuo H, Gandhi M, Edreira MM, et al: Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res 70: 1389-1397, 2010.
57. Stephen JK, Chitale D, Narra V, Chen K M, Sawhney R and Worsham MJ: DNA methylation in thyroid tumorigenesis. Cancers (Basel) 3: 1732-1743, 2011.
58. Zhang X, Li D, Li M, et al: MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development. Int J Cancer 134: 257-267, 2014.
59. Visone R, Russo L, Pallante P, et al: MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 14: 791-798, 2007.
60. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658, 2007.
61. Asangani IA, Rasheed SA, Nikolova DA, et al: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27: 2128-2136, 2008.
62. Sabatel C, Malvaux L, Bovy N, et al: MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS One 6: e16979, 2011.
63. Jazdzewski K, Boguslawska J, Jendrzejewski J, et al: Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J Clin Endocrinol Metab 96: E546-E553, 2011.
64. Sun Y, Yu S, Liu Y, Wang F, Liu Y and Xiao H: Expression of miRNAs in papillary thyroid carcinomas is associated with BRAF mutation and clinicopathological features in Chinese patients. Int J Endocrinol 2013: 128735, 2013.
65. Marini F, Luzi E and Brandi ML: MicroRNA role in thyroid cancer development. J Thyroid Res 2011: 407123, 2011.
66. Hudson J, Duncavage E, Tamburrino A, et al: Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma. Exp Mol Pathol 95: 62-67, 2013.
67. Ajith TA: Physiological relevance and theraeutic value of micro RNA in cancer. Front Pathol Genet 1: 15-19, 2013.
68. Chen J, Wang M, Guo M, Xie Y and Cong YS: miR-127 regulates cell proliferation and senescence by targeting BCL6. PLoS One 8: e80266, 2013.
69. Cahill S, Smyth P, Denning K, et al: Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Mol Cancer 6: 21, 2007.